Dr. Clay Siegall is Fully Utilizing Resources at Seattle Genetics To Bring a Revolution in Cancer Treatment

Dr. Clay Siegall has found a standing in the fight against diseases with a high rate of mortality such as cancer. He runs Seattle Genetics, a biotech firm that is in the forefront in research and development of targeted therapy drugs for such diseases. Besides money, Dr. Clay was inspired to start this venture by a personal experience with a loved one who was being treated for cancer. The treatment that included chemotherapy almost became fatal, which left him thinking of other ways that can heal the disease. He had always been interested in the combination of medicine and technology to fight disease. He desired to see patients who are facing life-threatening conditions regain hope.

Accomplishments

Since its inception almost two decades ago, Seattle Genetics has made notable strides in drug development. It prides on its first antibody-drug conjugate ADCetris that has since earned the FDA-approval. The drug has also shown three indications and attracted other like-minded investors such as Pfizer, Bayer, and Genentech among others. Besides this medicine, Seattle Genetics has more than 20 drugs in the development stages. These achievements give the firm a high standing in the industry as well as hope that traditional methods will soon be replaced with more effective ones.

How He Did It

Dr. Clay Siegall has had to fight several challenges such as financial hurdles to get to where he is today. His hard work saw him pull through and become profitable after ten years. He invested more in acquiring the best talent to form his sales team. This team has excellently represented Seattle Genetics bringing in customers in good numbers. Seattle Genetics has also done well in creating unique products that sell themselves in the market. Today, the firm is making large reaps in selling ADCetris, technology, and processes licensing as well as from production partnerships.

About Dr. Clay Siegall

Before venturing into Seattle Genetics, Dr. Clay Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute for six years. He had previously worked for the National Cancer Institute, National Institute of Health.

Dr. Clay Siegall serves on the board of directors of several organizations. They include the Fred Hutchinson Cancer Research Center, Mirna Therapeutics, and Alder BioPharmaceuticals.